Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid-sparing versus standard steroid regimen with daclizumab, mycophenolate mofetil, and sirolimus after renal transplantation
2005-003383-39Phase 4Completed
- Sponsor
- Roche
- Start
- Nov 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of daclizumab, mycophenolate mofetil, sirolimus and corticosteroids in kidney allograft rejection (2 arms), sponsored by Roche. Primary endpoint: Primary efficacy endpoint. Started Nov 2005; status: completed.
02
Drugs
daclizumabmycophenolate mofetilsirolimuscorticosteroids
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2005-003383-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003383-39.